KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Inventory (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Inventory for 8 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 16.35% to $9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2025, up 16.35% year-over-year, with the annual reading at $9.8 million for FY2025, 16.35% up from the prior year.
  • Inventory hit $9.8 million in Q4 2025 for Adaptive Biotechnologies, down from $9.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $21.0 million in Q1 2022 to a low of $8.4 million in Q2 2025.
  • Historically, Inventory has averaged $15.1 million across 5 years, with a median of $15.9 million in 2022.
  • Biggest five-year swings in Inventory: skyrocketed 76.65% in 2021 and later plummeted 41.58% in 2024.
  • Year by year, Inventory stood at $19.3 million in 2021, then dropped by 24.97% to $14.5 million in 2022, then decreased by 0.03% to $14.4 million in 2023, then crashed by 41.58% to $8.4 million in 2024, then grew by 16.35% to $9.8 million in 2025.
  • Business Quant data shows Inventory for ADPT at $9.8 million in Q4 2025, $9.9 million in Q3 2025, and $8.4 million in Q2 2025.